Syneos Health, Inc. which can be found using ticker (SYNH) have now 9 market analysts covering the stock. The analyst consensus now points to a rating of ‘hold’. The range between the high target price and low target price is between 43 and 40 with the average target price sitting at $42.56. Given that the stocks previous close was at $41.68 this would imply there is now a potential upside of 2.1%. Also worth taking note is the 50 day moving average now sits at $38.08 and the 200 day moving average is $42.34. The market cap for the company is 4.32B. The stock price is currently at: 41.69 USD
The potential market cap would be $4,412,274,700 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 28.95, revenue per share of 52.62 and a 3.17% return on assets.
Syneos Health, Inc. is a biopharmaceutical solutions company that utilizes outsourced clinical drug development and commercialization services. The Company operates through two business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The Clinical Solutions segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions (public relations, advertising, and medical communications), and consulting services. The Company’s customers include small, mid-sized, and large companies in the biopharmaceutical, biotechnology, and medical device industries.
